Výsledky vyhledávání

The effect of risankizumab on achieving minimal clinically important differences in patient‐reported outcomes in patients with psoriatic arthritis: results from KEEPsAKE 1 and 2

Autor: L.E. Kristensen, A.M. Soliman, K. Papp, L. Barcomb, A. Eldred, A. Östör

Publikováno v: Kristensen, L E, Soliman, A M, Papp, K, Barcomb, L, Eldred, A & Östör, A 2022, ' The effect of risankizumab on achieving minimal clinically important differences in patient-reported outcomes in patients with psoriatic arthritis : results from KEEPsAKE 1 and 2 ', Journal of the European Academy of Dermatology and Venereology, vol. 36, no. 11, pp. 2120-2129 . https://doi.org/10.1111/jdv.18475

BackgroundPsoriatic arthritis (PsA) is a chronic inflammatory disease that reduces the quality of life. This study assessed the effects of risankizumab (RZB) on the achievement of minimal clinically important differences (MCID) in patient-reported ou

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4fde280a2a06268a34dc1734d188df4f
https://doi.org/10.1111/jdv.18475

Zobrazit plný text záznamu

Effects of risankizumab on nail psoriasis in patients with active psoriatic arthritis: results from KEEPsAKE 1

Autor: L.E. Kristensen, A.M. Soliman, K. Papp, J.F. Merola, L. Barcomb, Z. Wang, A. Eldred, F. Behrens

Publikováno v: Kristensen, L E, Soliman, A M, Papp, K, Merola, J F, Barcomb, L, Wang, Z, Eldred, A & Behrens, F 2022, ' Effects of risankizumab on nail psoriasis in patients with active psoriatic arthritis : results from KEEPsAKE 1 ', Journal of the European Academy of Dermatology and Venereology, vol. 36, no. 5, pp. e389-e392 . https://doi.org/10.1111/jdv.17931

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07c81e6c67600825c95671030d9a17be
https://doi.org/10.1111/jdv.17931

Zobrazit plný text záznamu

POS1042 IMPACT OF RISANKIZUMAB ON IMPROVING HEALTH-RELATED QUALITY OF LIFE, WORK PRODUCTIVITY, AND REDUCING FATIGUE AMONG PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: A POOLED ANALYSIS OF TWO PHASE 3 CLINICAL TRIALS

Autor: L. E. Kristensen, A. M. Soliman, K. Papp, L. Barcomb, A. Eldred, Z. Wang, D. White, F. Behrens

Publikováno v: Annals of the Rheumatic Diseases. 81:837-838

BackgroundRisankizumab (RZB) has been approved in the UK and Europe for the treatment of adults with active PsA. Patient-reported outcomes (PROs) are important tools for understanding a therapy’s efficacy from the patient’s perspective.Objectives

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ad8a0056b84c6dd9d264fdcb8280c650
https://doi.org/10.1136/annrheumdis-2022-eular.1902

Zobrazit plný text záznamu

POS1024 EFFICACY AND SAFETY OF RISANKIZUMAB (RZB) FOR ACTIVE PSORIATIC ARTHRITIS (PsA): 52-WEEK RESULTS FROM KEEPsAKE 1

Autor: L. E. Kristensen, M. Keiserman, K. Papp, L. Mccasland, D. White, W. Lu, A. M. Soliman, A. Eldred, L. Barcomb, F. Behrens

Publikováno v: Annals of the Rheumatic Diseases. 81:823.2-824

BackgroundRZB, a humanized immunoglobulin G1 monoclonal antibody that specifically inhibits the p19 subunit of the human cytokine IL-23, is being investigated as a treatment for PsA.ObjectivesTo compare efficacy and safety of RZB vs. placebo (PBO) in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e950d5215f2734aade5672519f07d4f2
https://doi.org/10.1136/annrheumdis-2022-eular.1186

Zobrazit plný text záznamu

AB0901 Effects of Treatment with Risankizumab on Reducing Pain and Inflammation in Patients with Psoriatic Arthritis: An analysis of the KEEPsAKE -1 and -2 Trials

Autor: A. Ostor, S. Kwatra, C. Nduaka, M. Patel, A. M. Soliman, L. Barcomb, Z. Xue, H. Photowala, K. Papp

Publikováno v: Annals of the Rheumatic Diseases. 81:1579.1-1579

BackgroundRisankizumab (RZB), a monoclonal antibody that specifically inhibits interleukin 23, is being investigated as a treatment for adults with psoriatic arthritis (PsA).ObjectivesEvaluate the efficacy of RZB treatment on the reduction in pain an

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2d7b6d3317e857cc6402e5057d8cbe7e
https://doi.org/10.1136/annrheumdis-2022-eular.2189

Zobrazit plný text záznamu

AB0897 Impact of risankizumab on improving symptoms and health-related quality of life and reducing fatigue and pain among psoriatic arthritis patients with moderate-to-severe skin involvement: Evidence from two Phase III trials

Autor: K. Papp, A. M. Soliman, C. Kaufmann, L. Barcomb, Z. Wang, D. White, A. Ostor, L. E. Kristensen

Publikováno v: Annals of the Rheumatic Diseases. 81:1576.2-1577

BackgroundPsoriatic arthritis (PsA) greatly affects patient-reported health-related quality of life (HRQoL).ObjectivesTo assess the impact of risankizumab (RZB) on patient-reported outcomes (PROs) in patients with high skin burden using integrated ef

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5274114a89f56a2cf90df82597d70ed7
https://doi.org/10.1136/annrheumdis-2022-eular.1904

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání